343 related articles for article (PubMed ID: 25630467)
21. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.
Wootten D; Simms J; Koole C; Woodman OL; Summers RJ; Christopoulos A; Sexton PM
J Pharmacol Exp Ther; 2011 Feb; 336(2):540-50. PubMed ID: 21075839
[TBL] [Abstract][Full Text] [Related]
22. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.
Willard FS; Ho JD; Sloop KW
Adv Pharmacol; 2020; 88():173-191. PubMed ID: 32416867
[TBL] [Abstract][Full Text] [Related]
23. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
24. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
[TBL] [Abstract][Full Text] [Related]
25. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway.
Thompson A; Kanamarlapudi V
Biochem Pharmacol; 2015 Jan; 93(1):72-84. PubMed ID: 25449603
[TBL] [Abstract][Full Text] [Related]
26. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.
Zhang M; Robitaille M; Showalter AD; Huang X; Liu Y; Bhattacharjee A; Willard FS; Han J; Froese S; Wei L; Gaisano HY; Angers S; Sloop KW; Dai FF; Wheeler MB
Mol Cell Proteomics; 2014 Nov; 13(11):3049-62. PubMed ID: 25044020
[TBL] [Abstract][Full Text] [Related]
27. Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.
Koole C; Savage EE; Christopoulos A; Miller LJ; Sexton PM; Wootten D
Mol Endocrinol; 2013 Aug; 27(8):1234-44. PubMed ID: 23864649
[TBL] [Abstract][Full Text] [Related]
28. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain.
Tibaduiza EC; Chen C; Beinborn M
J Biol Chem; 2001 Oct; 276(41):37787-93. PubMed ID: 11498540
[TBL] [Abstract][Full Text] [Related]
29. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2.
Schepp W; Dehne K; Riedel T; Schmidtler J; Schaffer K; Classen M
Digestion; 1996; 57(6):398-405. PubMed ID: 8913701
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
31. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.
Beinborn M; Worrall CI; McBride EW; Kopin AS
Regul Pept; 2005 Aug; 130(1-2):1-6. PubMed ID: 15975668
[TBL] [Abstract][Full Text] [Related]
32. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG
J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947
[TBL] [Abstract][Full Text] [Related]
33. Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.
Angelone T; Filice E; Quintieri AM; Imbrogno S; Amodio N; Pasqua T; Pellegrino D; Mulè F; Cerra MC
Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):486-94. PubMed ID: 21186112
[TBL] [Abstract][Full Text] [Related]
34. Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1.
Furness SGB; Christopoulos A; Sexton PM; Wootten D
Biochem Pharmacol; 2018 Oct; 156():223-240. PubMed ID: 30149018
[TBL] [Abstract][Full Text] [Related]
35. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence.
Serre V; Dolci W; Schaerer E; Scrocchi L; Drucker D; Efrat S; Thorens B
Endocrinology; 1998 Nov; 139(11):4448-54. PubMed ID: 9794451
[TBL] [Abstract][Full Text] [Related]
36. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor.
Yusta B; Somwar R; Wang F; Munroe D; Grinstein S; Klip A; Drucker DJ
J Biol Chem; 1999 Oct; 274(43):30459-67. PubMed ID: 10521425
[TBL] [Abstract][Full Text] [Related]
37. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
Heller RS; Kieffer TJ; Habener JF
Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446
[TBL] [Abstract][Full Text] [Related]
38. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
40. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.
Roed SN; Wismann P; Underwood CR; Kulahin N; Iversen H; Cappelen KA; Schäffer L; Lehtonen J; Hecksher-Soerensen J; Secher A; Mathiesen JM; Bräuner-Osborne H; Whistler JL; Knudsen SM; Waldhoer M
Mol Cell Endocrinol; 2014 Feb; 382(2):938-49. PubMed ID: 24275181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
